Documente Academic
Documente Profesional
Documente Cultură
Ce este demena?
Declin al funciei cognitive dobndit (n 2 sau mai multe domenii cognitive) care apare n absena confuziei acute (delir) care determin disfuncionaliti (scderea memoriei, a abilitilor funcionale ) care nu au o alt cauz medical. DSM IV1
1. European Handbook of Neurological Management, edited by R. Hughes et al (European Federation of Neurological Societies), Blackwell Publishing, 2006.
Forme de demen
Demena cu corpi Lewy Boala Parkinson Boala Alzheimer i Demena cu corpi Lewy
Boala Alzheimer
5% 10% 65% 5% 7% 8%
Prevalena demenei %
AVC i demena
25 20
15%
23%
15
10%
10 5 0
7%
1
Lobo A. et al. Neurology. 2000;54(suppl 5):S4-S9.
10
Timp (ani)
100 90 80 70 60
100 90 80 70 60
50
examen 12 iniial 24 Luni 36 48
Control
Maximum
Minimum
Medie
1. Mintzer J. et al., 2002 AAGP Annual Meeting
Moderat
Sever
1. Perry EK et al. Neuropathol Appl Neurobiol. 1978;4:273-277; 2. Rodriquez-Puertas R et al. Synapse. 1997;26:341-350.;
N. basalis Meynert
Modificri colinergice majore n Boala Alzheimer Depleia de ACh: mai ales n stadiile moderate i Creterea cantitii severe1,3
de Ach
Pierderea receptorilor muscarinici (M2) 3,4 Pierderea receptorilor nicotinici (nAChR) 3,4
Celul glial
Butyryl cholinesteraza
HACU
ACh ACh
Colin + Acetat
Butyrylcholinesteraza
NOS
NO
1.Pugsley TA et al. Drug Development Research 1983; 3: 407-420; 2. Branconnier R.J. et al.; Psychopharmacology Bulletin 1983; 19: 726-730; 3. Shih Y.H. et al.; Life Sciences, Vol.36: 2145-2152; 4. Corosaniti M.T. et al.; Funct. Neurol. 1995; 10 (3): 151-155.
1. Corosaniti MT et al. Funct. Neurol. 1995; 10 (3): 151-155. 2. Vaucher E et al. Neuroscience 1997; 79 (3): 827-836.
PEP
Pramistar
Hidrolizarea Vasopresinei
funcia de memorie
Crete rezistena la extincie a procesului de invare1 Faciliteaz consolidarea informaiilor1 Inhib pierderile de memorie induse de hipoxie1 mbuntete capacitatea de rememorare1
1.Yoshimoto T et al. J. Pharmacobio-Dyn. 1987; 10: 730-735. 2. Nappi G et al.; Drugs of Today, 1994; 30(6):469-482.
8 spt 12 spt
60 pacieni cu tulburri cognitive i de memorie tratai 12 saptamni cu 1200 mg/zi Pramiracetam vs. Placebo . Scor Sandoz - Sandoz Clinical Assesment Geriatric Scale
Marini G et al. Advances in Therapy 1992; 9 (3): 136-146.
6
mbunirea funciei (%)
5 4 3 2 1 0 0 4
sptmni
pramiracetam placebo
p<0,01
12
p<0,05
4 spt
8 spt
12 spt
Studiu dublu orb 12 sapt, la pacieni cu tulburri de memorie, atenie, concentrare BSRT : Buschke Selective Reminding Test
Guazzi G. Simposio Memoria e farmaci, Siena 1991.
100
Ameliorare (%)
80 60 40 20 0
30 60 90 memorie verbal de scurt durat memorie verbal de lung durat concentrare
zile
Scarpazza P et al. Advances in Therapy 1993; 10 (5): 217-222.
10
15
20
25
De ce Pramistar
O mbuntire a
simptomelor psihometrice cum ar
memorare i
concentrare1,2
fi agitaia, strile
depresive, anxietatea2,3
1. Marini G. et al., Advances in Therapy, 1992, 9(3):136-146 2. Nappi G. et al. Drugs of Today 1994; 30 (6): 469-482. 3. Pugsley T.A. et al. Drug Development Research 1983; 3: 407-420.
Pramistar
faciliteaz nvarea i consolidarea memoriei1 crete rezistena la hipoxie cerebral2 previne apariia tulburrilor capacitii de nvare2 Indicat n : Tratamentul tulburrilor de memorie sau de concentrare degenerative sau vasculare, mai ales la vrstnici3
1.Marini G. et al., Advances in Therapy, 1992, 9(3):136-146; 2.Yoshimoto T et al. J. Pharmacobio-Dyn. 1987; 10: 730-735; 3. RCP Pramistar
Mod de administrare
1 comprimat de 600 mg de 2 ori pe zi